Targeting EZH2 in Cancer

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2016 Feb 5

PMID 26845405

Citations 747

Authors

Kimberly H Kim

Charles W M Roberts

Affiliations

Soon will be listed here.

Abstract

Recent genomic studies have resulted in an emerging understanding of the role of chromatin regulators in the development of cancer. EZH2, a histone methyl transferase subunit of a Polycomb repressor complex, is recurrently mutated in several forms of cancer and is highly expressed in numerous others. Notably, both gain-of-function and loss-of-function mutations occur in cancers but are associated with distinct cancer types. Here we review the spectrum of EZH2-associated mutations, discuss the mechanisms underlying EZH2 function, and synthesize a unifying perspective that the promotion of cancer arises from disruption of the role of EZH2 as a master regulator of transcription. We further discuss EZH2 inhibitors that are now showing early signs of promise in clinical trials and also additional strategies to combat roles of EZH2 in cancer.

Citing Articles

Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer.

Yang R, Fei L, Xue Y, Zhang Y, Hu Q, Guo L J Cell Mol Med. 2025; 29(5):e70384.

PMID: 40070134 PMC: 11897054. DOI: 10.1111/jcmm.70384.

Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.

Yang J, Zhou F, Luo X, Fang Y, Wang X, Liu X Cell Death Discov. 2025; 11(1):84.

PMID: 40032852 PMC: 11876437. DOI: 10.1038/s41420-025-02366-3.

ROS regulates circadian rhythms by modulating Ezh2 interactions with clock proteins.

Zhang H, Li K, Wang Y, Wei C, Gao Y, Ren-Zhou Redox Biol. 2025; 81:103526.

PMID: 39952198 PMC: 11875201. DOI: 10.1016/j.redox.2025.103526.

Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial.

Oppelt P, Puram S, Liu J, Ley J, Adkins D Cancers (Basel). 2025; 17(3).

PMID: 39941804 PMC: 11816339. DOI: 10.3390/cancers17030437.

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction.

Liu R, Li Z, Chen R, Fang Z, Liu Z, Liu H Nat Commun. 2025; 16(1):1206.

PMID: 39885217 PMC: 11782520. DOI: 10.1038/s41467-025-56506-5.

References

Orkin S, Hochedlinger K . Chromatin connections to pluripotency and cellular reprogramming. Cell. 2011; 145(6):835-50. PMC: 4858411. DOI: 10.1016/j.cell.2011.05.019. View

Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K . Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med. 2005; 16(2):349-53. View

Chen Y, Lin M, Wang H, Chan C, Jiang L, Ngai S . Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics. 2007; 7(17):3097-104. DOI: 10.1002/pmic.200700019. View

Lee J, Lee J, Kim H, Kim K, Park H, Kim J . EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012; 48(4):572-86. DOI: 10.1016/j.molcel.2012.09.004. View

Score J, Hidalgo-Curtis C, Jones A, Winkelmann N, Skinner A, Ward D . Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 2011; 119(5):1208-13. DOI: 10.1182/blood-2011-07-367243. View

Fujii S, Ito K, Ito Y, Ochiai A . Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008; 283(25):17324-32. PMC: 2427338. DOI: 10.1074/jbc.M800224200. View

Huether R, Dong L, Chen X, Wu G, Parker M, Wei L . The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun. 2014; 5:3630. PMC: 4119022. DOI: 10.1038/ncomms4630. View

Gibaja V, Shen F, Harari J, Korn J, Ruddy D, Saenz-Vash V . Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene. 2015; 35(5):558-66. PMC: 4744243. DOI: 10.1038/onc.2015.114. View

Baude A, Lindroth A, Plass C . PRC2 loss amplifies Ras signaling in cancer. Nat Genet. 2014; 46(11):1154-5. DOI: 10.1038/ng.3124. View

10.

Jia N, Li Q, Tao X, Wang J, Hua K, Feng W . Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma. Oncol Lett. 2014; 8(5):2049-2054. PMC: 4186594. DOI: 10.3892/ol.2014.2437. View

11.

Eskander R, Ji T, Huynh B, Wardeh R, Randall L, Hoang B . Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013; 23(6):997-1005. PMC: 3694282. DOI: 10.1097/IGC.0b013e318296a265. View

12.

Smits M, Mir S, Nilsson R, Van der Stoop P, Niers J, Marquez V . Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One. 2011; 6(1):e16282. PMC: 3030563. DOI: 10.1371/journal.pone.0016282. View

13.

Creyghton M, Cheng A, Welstead G, Kooistra T, Carey B, Steine E . Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A. 2010; 107(50):21931-6. PMC: 3003124. DOI: 10.1073/pnas.1016071107. View

14.

Hussain M, Rao M, Humphries A, Hong J, Liu F, Yang M . Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 2009; 69(8):3570-8. PMC: 8374472. DOI: 10.1158/0008-5472.CAN-08-2807. View

15.

Chen H, Lin I, Chen Y, Chang K, Wu M, Su W . A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. Clin Invest Med. 2012; 35(1):E1-11. DOI: 10.25011/cim.v35i1.16100. View

16.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

17.

Lewis P, Muller M, Koletsky M, Cordero F, Lin S, Banaszynski L . Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134):857-61. PMC: 3951439. DOI: 10.1126/science.1232245. View

18.

Francis N, Saurin A, Shao Z, Kingston R . Reconstitution of a functional core polycomb repressive complex. Mol Cell. 2001; 8(3):545-56. DOI: 10.1016/s1097-2765(01)00316-1. View

19.

Li H, Ma X, Wang J, Koontz J, Nucci M, Sklar J . Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc Natl Acad Sci U S A. 2007; 104(50):20001-6. PMC: 2148412. DOI: 10.1073/pnas.0709986104. View

20.

Herrera-Merchan A, Arranz L, Ligos J, de Molina A, Dominguez O, Gonzalez S . Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun. 2012; 3:623. DOI: 10.1038/ncomms1623. View